MetabolismNews.net

Metabolism Xagena

The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor with prefilled cartridge ), a new, monthly single-dose administration option. The ...


Evidence is mounting that a diet mimicking the effects of fasting has health benefits beyond weight loss, with a new study indicating that it may reduce symptoms of multiple sclerosis. Researchers di ...


Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholester ...


The Phase 3 SPIRE-AI ( AutoInjector ) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor ( PCSK9i ) Bococizumab administered with a pre-filled pen met its co-primary ...


New detailed data from the phase 3 GAUSS-3 ( Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 ) trial evaluating Evolocumab ( Repatha ) in patients with high cho ...


The composition of the gut microbiota and excessive ingestion of high-fat diets ( HFD ) are considered to be important factors for development of obesity. Researchers have described a coherent mec ...


Previous studies have suggested that Niacin treatment raises glucose levels in patients with diabetes mellitus and may increase the risk of developing diabetes. Researchers performed a meta-analysis ...


Alirocumab ( Praluent ) lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials. Final d ...


Inhibition of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) has been intensively studied to lower low-density lipoprotein cholesterol ( LDL-C ) levels. The purpose of this meta-analysis ...


The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events ( HPS2-THRIVE ) showed that adding extended-release Niacin-Laropiprant ( ERN-LRPT ) to statin provided no incre ...


Despite current standard-of-care, many patients at high cardiovascular disease ( CVD ) risk still have elevated low-density lipoprotein cholesterol ( LDL-C ). Alirocumab ( Praluent ) is a fully huma ...


Phase 2b TULIP study results with CETP inhibitor, TA-8995, a drug in the field of dyslipidemia, were published in the Lancet. The peer-reviewed article is entitled Cholesterol ester transfer protein i ...


Results from ETC-1002-009, a phase 2b study evaluating the efficacy and safety of ETC-1002 ( Bempedoic acid ) compared with placebo in patients with hypercholesterolemia on stable statin therapy, were ...


Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol ( LDL ...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab ( Praluent ), a fully human monoclonal antibody to proprotein convertase subtilisi ...


The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro ) in patients with familial hypercholesterolaemia taking maximally tolerated lipid-lowerin ...


One-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the phase 2 ( OSLER-1 ) and phase 3 ( OSLER-2 ) open-label extension studies of Evolocumab ( Repatha ), a ...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published in The New Engla ...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE ) and glomerular filtration rate ( GFR ) in patients wit ...


The purpose was to study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome ( OHS ) as compared with ...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus ( T2DM ) patients. The ABCD score, which comprise age, BMI, C-peptide level, and duration of type ...


It is unclear whether an intensive program of weight loss combined with exercise prevents the onset of knee pain among those at high risk. Researchers have examined whether an intensive lifestyle in ...


Statins are the treatment of choice for dyslipidemia, primarily lowering elevated LDL-C levels and reducing the occurrence of major cardiovascular events. In June 2011, the FDA ( Food and Drug Admin ...


Adding the drug Ezetimibe to treatment with Simvastatin lowers the risk of future cardiovascular problems, including myocardial infarction and stroke, in high-risk patients with acute coronary syndrom ...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda ( Liraglutide 3 mg ), the first once-daily human glucagon-like peptide-1 ( GLP-1 ) analogue for the t ...


It is unclear whether high-density lipoprotein ( HDL ) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of ...


The European Medicines Agency ( EMA ) has recommended granting a marketing authorisation for Mysimba ( Naltrexone / Bupropion ) for weight management of overweight or obese adults. The medicine is rec ...


Data, published in The Lancet, from two phase 3 studies, RUTHERFORD-2 and TESLA with Evolocumab, a novel investigational low-density lipoprotein cholesterol ( LDL-C )-lowering medication, resulted in ...


Results from four Phase 3 ODYSSEY trials of Alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin / k ...


By inhibiting apolipoprotein B ( ApoB ) synthesis, Mipomersen ( Kynamro ) can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients. The purpose of a study was to ascer ...


Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol ( LDL-C ) and accel ...


A meta-analysis of individual participant data of eight prospective cohort studies from Europe and the US has investigated the association between serum 25-hydroxyvitamin D concentrations [ 25(OH)D ] ...


Thirty-six percent of adults in the United States are obese, and many cannot lose sufficient weight to improve health with lifestyle interventions alone. Researches have conducted a systematic revi ...


National and international guidelines recommend fasting lipid panel measurement for risk stratification of patients for prevention of cardiovascular events. Yet, the prognostic value of fasting versus ...


Vitamin-D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of Vitamin-D on diso ...


In short-term randomized trials ( duration, 1 to 2 years ), bariatric surgery has been associated with improvement in type 2 diabetes mellitus. Researchers have assessed outcomes 3 years after the ...


Efficacy and safety of Alirocumab were compared with Ezetimibe ( Ezetrol, Zetia ) in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy ...


Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced pla ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of Calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


Amgen has announced that the Phase 3 RUTHERFORD-2 ( RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2 ) trial evaluating Evolocumab in combination ...


Current osteoporosis medications increase bone mineral density ( BMD ) modestly and reduce, but do not eliminate, fracture risk. Attempts to improve efficacy by administering anabolic agents and bisph ...


Findings from recent meta-analyses of Vitamin D supplementation without co-administration of calcium have not shown fracture prevention, possibly because of insufficient power or inappropriate doses, ...


The results from a phase 2 trial evaluating Romosozumab in postmenopausal women with low bone mineral density ( BMD ) were published in the New England Journal of Medicine ( NEJM ).The trial demonstra ...


Rhizomelic chondrodysplasia punctata ( RCDP ) is a rare disorder of peroxisomal metabolism, with an estimated incidence of 1:100.000. There are 3 genetic subtypes. RCDP type 1, caused by mutations in ...


Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. A study has assessed the efficacy and safety of the microsomal triglyceride transfer protein ( MTP ) inh ...


Enteral nutrition is recommended for patients in the intensive-care unit ( ICU ), but it does not consistently achieve nutritional goals.Researchers have assessed whether delivery of 100% of the energ ...


Statins are commonly prescribed for management of dyslipidaemia and cardiovascular disease. Increased fitness is also associated with low mortality and is recommended as an essential part of promoting ...


Osteoporosis medications increase bone-mineral density ( BMD ) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy.Researchers ...


Low levels of total 25-Hydroxyvitamin D are common among black Americans. Vitamin D-binding protein ( DBP ) has not been considered in the assessment of vitamin D deficiency.In the Healthy Aging in Ne ...


Arena Pharmaceuticals has officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Belviq, a medicin ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati